Trade Applied Therapeutics Inc - APLT CFD
Add to favourite- Summary
- Historical Data
Spread | 0.0500 | ||||||||
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023346% | ||||||||
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001124% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 50.00% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
Prev. Close | N/A |
Open | 0.3969 |
1-Year Change | -93.14% |
Day's Range | 0.3969 - 0.4001 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Apr 24, 2025 | 0.4001 | 0.0032 | 0.81% | 0.3969 | 0.4001 | 0.3969 |
Apr 15, 2025 | 0.3365 | -0.0006 | -0.18% | 0.3371 | 0.3371 | 0.3365 |
Apr 8, 2025 | 0.3818 | -0.0082 | -2.10% | 0.3900 | 0.3901 | 0.3818 |
Apr 7, 2025 | 0.3956 | 0.0056 | 1.44% | 0.3900 | 0.3956 | 0.3791 |
Apr 4, 2025 | 0.4098 | 0.0294 | 7.73% | 0.3804 | 0.4213 | 0.3804 |
Apr 3, 2025 | 0.4092 | 0.0078 | 1.94% | 0.4014 | 0.4092 | 0.3818 |
Apr 2, 2025 | 0.4380 | 0.0185 | 4.41% | 0.4195 | 0.4393 | 0.4126 |
Apr 1, 2025 | 0.4418 | -0.0305 | -6.46% | 0.4723 | 0.4739 | 0.4380 |
Mar 31, 2025 | 0.4648 | 0.0198 | 4.45% | 0.4450 | 0.4926 | 0.4450 |
Mar 28, 2025 | 0.4922 | -0.0278 | -5.35% | 0.5200 | 0.5266 | 0.4884 |
Mar 27, 2025 | 0.5208 | 0.0108 | 2.12% | 0.5100 | 0.5317 | 0.5066 |
Mar 26, 2025 | 0.5011 | -0.0179 | -3.45% | 0.5190 | 0.5301 | 0.5011 |
Mar 25, 2025 | 0.5262 | -0.0098 | -1.83% | 0.5360 | 0.5360 | 0.5067 |
Mar 24, 2025 | 0.5345 | -0.0066 | -1.22% | 0.5411 | 0.5574 | 0.5202 |
Mar 21, 2025 | 0.5300 | 0.0602 | 12.81% | 0.4698 | 0.5841 | 0.4612 |
Mar 20, 2025 | 0.4780 | -0.0021 | -0.44% | 0.4801 | 0.4900 | 0.4671 |
Mar 19, 2025 | 0.4764 | -0.0136 | -2.78% | 0.4900 | 0.5002 | 0.4763 |
Mar 18, 2025 | 0.4974 | -0.0325 | -6.13% | 0.5299 | 0.5299 | 0.4788 |
Mar 17, 2025 | 0.5190 | 0.0309 | 6.33% | 0.4881 | 0.5240 | 0.4793 |
Mar 14, 2025 | 0.4863 | 0.0063 | 1.31% | 0.4800 | 0.5284 | 0.4749 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 20
- 100
- 500
- 1000
- 10000
Applied Therapeutics, Inc. Company profile
About Applied Therapeutics Inc
Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on developing a pipeline of product candidates against validated molecular targets in indications of high unmet medical need. The Company’s molecular target is aldose reductase (AR), an enzyme that converts glucose to sorbitol under oxidative stress conditions. Its product candidates include AT-007, AT-001, AT-003 and AT-104. The Company’s AT-007 is a central nervous system (CNS) penetrant ARI, which is developed for the treatment of galactosemia. AT-001 is an aldose reductase inhibitor (ARI) with exposure and nerve permeability. AT-001 is developed for the treatment of diabetic cardiomyopathy (DbCM), fatal fibrosis of the heart. Its AT-003 is an ARI designed to cross through the back of the eye when dosed orally. AT-003 is developed for the treatment of diabetic retinopathy (DR). AT-104 is a dual selective PI3K inhibitor in preclinical development for T Cell Acute Lymphoblastic Leukemia (T-ALL).
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Applied Therapeutics Inc revenues was not reported. Net loss increased 12% to $105.6M. Higher net loss reflects General and administrative - Balancing increase of 66% to $15.7M (expense), Stock-based Compensation in SGA increase of 55% to $8.4M (expense), Other general & administrative expenses increase of 73% to $5.4M (expense).
Industry: | Bio Therapeutic Drugs |
545 5Th Avenue, Suite 1400
NEW YORK
NEW YORK 10017
US
News

ECB interest-rate forecasts – Projections for the next five years
The European Central Bank (ECB) plays a pivotal role in the economic stability of the eurozone, meaning ECB interest-rate forecasts are key to understanding how financial and economic scenarios might evolve.
14:37, 10 April 2025
BlackRock shareholders: Who owns the most BLK stock?
BlackRock is the leading asset manager in the world – but who are its biggest shareholders? Read on to find out.
13:46, 9 April 2025
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
10:28, 9 April 2025
Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
08:19, 9 April 2025
JasmyCoin price predictions 2025-2030: Third-party price target
How might JASMY behave in the future?
16:13, 8 April 2025
Australian interest-rate projections: where will rates be in 5 years?
As one of the most closely watched economic indicators, Australian interest-rate projections offer valuable insight into the future of the country’s economy.
21:37, 7 April 2025
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025People also watch
Still looking for a broker you can trust?
Join the 720,000+ traders worldwide that chose to trade with Capital.com